Article
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Thoracic cancer - 1 Jan 2017
Fukuda Minoru, Shimada Midori, Kitazaki Takeshi, Nagashima Seiji, Hashiguchi Kohji, Ebi Noriyuki, Takayama Koichi, Nakanishi Yoichi, Semba Hiroshi, Harada Taishi, Seto Takashi, Okamoto Isamu, Ichinose Yukito, Sugio Kenji
Abstract excerpt
BACKGROUND: Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.